Welcome to our dedicated page for Bioceres Crop Solutions news (Ticker: BIOX), a resource for investors and traders seeking the latest updates and insights on Bioceres Crop Solutions stock.
Bioceres Crop Solutions Corp. reports developments tied to crop productivity technologies for agricultural markets, including seeds, seed traits, seed treatments, biologicals, adjuvants, fertilizers, crop protection products and crop nutrition. Its recurring updates focus on operating results across crop protection, seed and integrated products, and crop nutrition, with frequent discussion of product mix, margins, working-capital discipline and conditions in Argentina.
Bioceres also announces collaboration and commercialization activity for HB4 wheat, a trait platform positioned for climate-resilient wheat production, as well as updates on capital structure matters and asset-related disputes affecting the business. Bioceres presents financial results under IFRS and regularly schedules calls around quarterly and full-year reporting periods.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) has received approval from the USDA for the cultivation of its HB4 drought-tolerant wheat in the United States. The USDA's Animal and Plant Health Inspection Service (APHIS) concluded that HB4 wheat does not pose an increased plant pest risk compared to conventional wheat. This decision complements the FDA's previous favorable review for food and feed use.
The United States, the fourth-largest wheat producer globally, joins Argentina, Brazil, and Paraguay in approving HB4 wheat production. Several other countries have approved the technology for food and feed use. Bioceres is also pursuing field trials in Australia for potential production approval. The company will provide more details on its HB4 wheat platform during its upcoming Earnings Call on September 10th.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX), a leader in agricultural productivity solutions, has announced a conference call to discuss its fiscal fourth quarter and full year 2024 financial results. The call is scheduled for Tuesday, September 10, 2024, at 8:30 a.m. Eastern Time. Key company executives, including CEO Federico Trucco and CFO Enrique Lopez Lecube, will host the call, which will be followed by a Q&A session. A press release detailing the results will be issued before the call. The conference will include a presentation accessible via webcast or the company's investor relations website. Interested parties can join using the provided toll-free and international dial-in numbers, with the conference ID 763481. A replay of the call will be available until September 17, 2024.
Bioceres Crop Solutions (NASDAQ: BIOX) reported its fiscal third quarter 2024 results, with total revenues of $84.0 million, down from $93.6 million in 3Q23.
The decrease was largely due to a $17 million drop in the Syngenta agreement compensatory payment.
GAAP net income stood at $9.8 million, while adjusted EBITDA was $21.1 million, both significantly lower than the previous year's figures.
Key developments include regulatory approval in Brazil for bio-insecticidal solutions and positive performance of HB4 Soy varieties, yielding a 7% improvement.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) CEO Federico Trucco to speak at the 2024 BMO Global Farm to Market Conference. Mr. Trucco will participate in the 'Agtech Disruption Across the Farming Value Chain' panel and conduct one-on-one meetings, aiming to showcase the company's innovations and future prospects.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) received approval from Brazil’s Ministry of Agriculture for three new bio-insecticidal/nematicidal solutions derived from inactivated cells of their Burkholderia platform. These products offer enhanced effectiveness, precision, and cost-competitiveness compared to chemical alternatives, marking a significant milestone in the Brazilian market. With a rapidly growing bio-control sector, this approval paves the way for future product launches and strengthens Bioceres' position in the global market.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) will host a conference call on May 14, 2024, to discuss its fiscal third quarter 2024 financial results. The call will be led by the Chairman & CEO, CFO, and Head of Investor Relations. The results will be issued in a press release prior to the call, with a webcast available. Investors can access the call using the provided information.
Summary not available.
Summary not available.
Summary not available.
Summary not available.